Psychotherapy combined with drug therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome: A randomized controlled trial.

OBJECTIVES: To explore the efficacy of psychotherapy combined with drug therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome. METHODS: A total of 156 patients with category III chronic prostatitis/chronic pelvic pain syndrome were randomly divided into two groups: the control group of 78 patients receiving routine medication; and the intervention group of 78 patients receiving psychological intervention therapy combined with routine medications. Treatment courses were for 3 months. The end-points were the response rate of the National Institutes of Health Chronic Prostatitis Symptom Index, International Index of Erectile Function-5, Self-Rating Anxiety Scale, Self-Rating Depression Scale and expressed prostatic secretion-white blood cells. RESULTS: After 3 months, the average scores of the National Institutes of Health Chronic Prostatitis Symptom Index decreased to 10.1 ± 5.0 in the control group compared with 14.1 ± 4.9 in the intervention group; thus, significant differences were observed between the two groups in the study (P < 0.001). The average scores of the International Index of Erectile Function-5 were improved in the two groups, but compared with the control group, a more marked improvement was detected in the psychological intervention group, and there was a significant difference between the two groups (P < 0.001). There was significant difference between the two groups in terms of the Self-Rating Anxiety Scale and Self-Rating Depression Scale scores (P < 0.001). Expressed prostatic secretion-white blood cell counts significantly decreased to 4.4 ± 3.5 in the control group compared with 9.8 ± 3.4 in the intervention group (P < 0.001). CONCLUSIONS: Psychological intervention therapy can effectively improve the psychological status and sexual function in patients with category III chronic prostatitis/chronic pelvic pain syndrome than the routine medication.

miR-205-5p inhibits cell migration and invasion in prostatic carcinoma by targeting ZEB1.

Many studies have demonstrated that miRNAs have influence on tumorigenesis and progression of human cancers, including invasion and migration. Thus, the role of miR-205/ZEB1 axis for the migration and invasion of prostate cancer cells was explored in the present study. The miR-205-5p and zinc finger E-box binding homeobox 1 (ZEB1) mRNA expression levels were observed in prostate cancer tissues or cell lines via reverse transcription-quantitative PCR (RT-qPCR), and the protein level of ZEB1 was measured by western blotting. Dual-Luciferase Reporter Assay was used to verify the relationship between miR-205-5p and ZEB1. In addition, cell migration and invasion was measured by Transwell assay. The results revealed that, compared with the control, downregulation of miR-205-5p was detected in prostate cancer tissues and cell lines, and miR-205-5p overexpression was found to inhibit cell migration and invasion. Moreover, miR-205-5p was confirmed to directly target ZEB1 in prostate cancer. Importantly, ZEB1 was identified to weaken the inhibitory effect of miR-205-5p in prostate cancer. In conclusion, miR-205-5p inhibited cell migration and invasion in prostatic carcinoma by targeting ZEB1 and miR-205-5p/ZEB1 axis shows potential to be developed in therapeutic strategies for prostate cancer.